Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 141

1.

A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.

Efficace F, Boccadoro M, Palumbo A, Petrucci MT, Cottone F, Cannella L, Zamagni E, Niscola P, Kyriakou C, Caravita T, Offidani M, Mandelli F, Cavo M.

Health Qual Life Outcomes. 2018 Jun 18;16(1):127. doi: 10.1186/s12955-018-0953-4.

2.

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.

Breccia M, Efficace F, Iurlo A, Luciano L, Abruzzese E, Gozzini A, Pregno P, Tiribelli M, Rosti G, Minotti G.

Expert Opin Drug Saf. 2018 Jun;17(6):623-628. doi: 10.1080/14740338.2018.1480719. Epub 2018 May 30. Review.

PMID:
29845876
3.

Patient-reported outcome assessment in acute leukemias: Moving beyond the barriers.

Efficace F, Cottone F, Sparano F, Lo-Coco F.

Cancer. 2018 Jul 15;124(14):3066-3067. doi: 10.1002/cncr.31521. Epub 2018 Apr 30. No abstract available.

PMID:
29710399
4.

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.

Caocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, De Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, La Nasa G, Foà R, Breccia M.

Am J Hematol. 2018 Jul;93(7):E159-E161. doi: 10.1002/ajh.25102. Epub 2018 Apr 28. No abstract available.

PMID:
29633312
5.

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.

Stauder R, Yu G, Koinig KA, Bagguley T, Fenaux P, Symeonidis A, Sanz G, Cermak J, Mittelman M, Hellström-Lindberg E, Langemeijer S, Holm MS, Mądry K, Malcovati L, Tatic A, Germing U, Savic A, van Marrewijk C, Guerci-Bresler A, Luño E, Droste J, Efficace F, Smith A, Bowen D, de Witte T.

Leukemia. 2018 Jun;32(6):1380-1392. doi: 10.1038/s41375-018-0089-x. Epub 2018 Mar 6.

6.

Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review.

Sparano F, Cavo M, Niscola P, Caravita T, Efficace F.

Support Care Cancer. 2018 Jul;26(7):2075-2090. doi: 10.1007/s00520-018-4137-x. Epub 2018 Mar 20. Review.

PMID:
29560502
7.

Sexual health in patients with hematological malignancies: a neglected issue.

Niscola P, Efficace F, Abruzzese E.

Support Care Cancer. 2018 Jun;26(6):1699-1701. doi: 10.1007/s00520-018-4124-2. Epub 2018 Mar 3.

PMID:
29502153
8.

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

Efficace F, Castagnetti F, Martino B, Breccia M, D'Adda M, Angelucci E, Stagno F, Cottone F, Malato A, Trabacchi E, Capalbo SF, Gobbi M, Visani G, Salvucci M, Capodanno I, Tosi P, Tiribelli M, Scortechini AR, Levato L, Maino E, Binotto G, Gugliotta G, Vignetti M, Baccarani M, Rosti G.

Cancer. 2018 May 15;124(10):2228-2237. doi: 10.1002/cncr.31323. Epub 2018 Mar 2.

PMID:
29499087
9.

Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPiC study qualitative protocol.

Retzer A, Keeley T, Ahmed K, Armes J, Brown JM, Calman L, Copland C, Efficace F, Gavin A, Glaser A, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Mercieca-Bebber R, King MT, Calvert M, Kyte D.

BMJ Open. 2018 Feb 3;8(2):e017282. doi: 10.1136/bmjopen-2017-017282.

10.

Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.

Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A, Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Borin L, Di Tucci AA, Zhang H, Sprangers M, Vignetti M, Mandelli F.

Cancer. 2018 Mar 15;124(6):1251-1259. doi: 10.1002/cncr.31193. Epub 2017 Dec 12.

PMID:
29231969
11.

Early Palliative Care in Patients With Hematological Malignancies: Where Do We Go From Here?

Niscola P, Tendas A, Efficace F.

J Pain Symptom Manage. 2018 Apr;55(4):e1-e2. doi: 10.1016/j.jpainsymman.2017.11.023. Epub 2017 Nov 28. No abstract available.

PMID:
29191722
12.

International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

van de Poll-Franse L, Oerlemans S, Bredart A, Kyriakou C, Sztankay M, Pallua S, Daniëls L, Creutzberg CL, Cocks K, Malak S, Caocci G, Molica S, Chie W, Efficace F; EORTC Quality of Life Group.

Qual Life Res. 2018 Feb;27(2):333-345. doi: 10.1007/s11136-017-1718-y. Epub 2017 Nov 10.

13.

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.

Breccia M, Baccarani M, Rosti G, Cottone F, Cannella L, Guilhot F, Vignetti M, Efficace F.

Health Qual Life Outcomes. 2017 Oct 18;15(1):204. doi: 10.1186/s12955-017-0788-4.

14.

A cross-cultural convergent parallel mixed methods study of what makes a cancer-related symptom or functional health problem clinically important.

Giesinger JM, Aaronson NK, Arraras JI, Efficace F, Groenvold M, Kieffer JM, Loth FL, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B; EORTC Quality of Life Group.

Psychooncology. 2018 Feb;27(2):548-555. doi: 10.1002/pon.4548. Epub 2017 Sep 21.

PMID:
28857424
15.

Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?

Efficace F, Gaidano G, Lo-Coco F.

Blood. 2017 Aug 17;130(7):859-866. doi: 10.1182/blood-2017-03-737403. Epub 2017 Jul 10. Review.

PMID:
28694324
16.

Are chronic myeloid leukemia patients ready to stop long-term treatment?

Breccia M, Efficace F.

Leuk Lymphoma. 2017 Dec;58(12):2976-2978. doi: 10.1080/10428194.2017.1330476. Epub 2017 May 23. No abstract available.

PMID:
28535695
17.

International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer.

van Leeuwen M, Kieffer JM, Efficace F, Fosså SD, Bolla M, Collette L, Colombel M, De Giorgi U, Holzner B, van de Poll-Franse LV, van Poppel H, White J, de Wit R, Osanto S, Aaronson NK; European Organisation for Research and Treatment of Cancer Quality of Life Group; Genito-Urinary Cancers Group and Radiation Oncology Group; and the NCRN Testis Clinical Studies Group.

Health Qual Life Outcomes. 2017 May 11;15(1):97. doi: 10.1186/s12955-017-0670-4.

18.

Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms.

Goel S, Paoli C, Iurlo A, Pereira A, Efficace F, Barbui T, Tefferi A, Vannucchi AM, Cervantes F.

Eur J Haematol. 2017 Jul;99(1):36-41. doi: 10.1111/ejh.12887. Epub 2017 May 5.

PMID:
28370510
19.

The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors.

Efficace F, Cannella L.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):170-179. Review.

PMID:
27913477
20.

Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies.

Efficace F, Breccia M, Cottone F, Okumura I, Doro M, Riccardi F, Rosti G, Baccarani M.

Support Care Cancer. 2016 Dec;24(12):4887-4894. Epub 2016 Jul 23.

PMID:
27448405

Supplemental Content

Loading ...
Support Center